SCHEMBL2784643

SCHEMBL2784643

CCCCCCCC=CCCCCCOC(C)(C)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.51
PPARA Q07869 4/20 0.51
TERT O14746 3/20 0.51
PTPN1 P18031 3/20 0.51
PPARD Q03181 3/20 0.51
TOP1 P11387 3/20 0.51
BLM P54132 3/20 0.51
HSD17B10 Q99714 3/20 0.51
MAPT P10636 2/20 0.51
FABP4 P15090 2/20 0.51
GMNN O75496 2/20 0.51
USP2 O75604 2/20 0.51
CYP1A2 P05177 2/20 0.51
POLB P06746 2/20 0.51
CYP2C9 P11712 2/20 0.51
APEX1 P27695 2/20 0.51
CYP2C19 P33261 2/20 0.51
RECQL P46063 2/20 0.51
DUSP3 P51452 2/20 0.51
LMNA P02545 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2784638 1.00 PPARG (0.51) PPARGPPARATERTPTPN1PPARD
SCHEMBL18944781 0.94 PPARG (0.54) PPARGPPARAPPARDBLMHSD17B10
SCHEMBL18944615 0.94 PPARG (0.54) PPARGPPARAPPARDBLMHSD17B10
SCHEMBL18944782 0.90 ALDH1A1 (0.54) PPARGPPARAPPARDBLMHSD17B10
SCHEMBL2785037 0.89 NAAA (0.45) PPARGPPARAPTPN1PPARDHSD17B10
SCHEMBL20915214 0.89 NAAA (0.45) PPARGPPARAPTPN1PPARDHSD17B10
SCHEMBL11240792 0.89 NAAA (0.45) PPARGPPARAPTPN1PPARDHSD17B10
SCHEMBL20936508 0.89 NAAA (0.45) PPARGPPARAPTPN1PPARDHSD17B10
SCHEMBL20936457 0.89 NAAA (0.45) PPARGPPARAPTPN1PPARDHSD17B10
SCHEMBL20915341 0.89 NAAA (0.45) PPARGPPARAPTPN1PPARDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221439-A1 POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS PRONOVA BIOPHARMA NORGE AS (NO) 2014-08-07 US disclosed
US-8735436-B2 Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas PRONOVA BIOPHARMA NORGE AS (NO) 2014-05-27 US disclosed
US-20120122940-A1 POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS PRONOVA BIOPHARMA NORGE AS (NO) 2012-05-17 US disclosed
WO-2010128401-A9 POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS PRONOVA BIOPHARMA NORGE AS (NO) 2011-12-08 WO disclosed
WO-2010128401-A1 POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS PRONOVA BIOPHARMA NORGE AS (NO) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122940-A1 POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS FFAR2, FFAR3, FFAR1 PPARG 53/4885PPARA 94/4885TERT 1837/4885
US-20140221439-A1 POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS FFAR2, FFAR3, FFAR1 PPARG 55/4885PPARA 92/4885TERT 1840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.